Elamin H. Elbasha, PhD
Distinguished Scientist, Outcomes Research
Merck Research Laboratories
Health Economic Statistics
PO Box 1000 UG1C-60
North Wales,
PA
USA
19454-1099
Papers:
2E-5
COST-EFFECTIVENESS OF BEZLOTOXUMAB+STANDARD OF CARE (SOC) VERSUS PLACEBO+SOC FOR THE PREVENTION OF RECURRENT CLOSTRIDIUM DIFFICILE INFECTION IN THE UNITED STATES